02.27.24 -- Novo Holdings Clarifies, But Competitors Circling Catalent

It takes a certain trained perspicuity to identify the CDMO right for you. If you are a small biotech, says CEO Matthias Schroff, you most likely will not have the weight to ensure an external partner’s “real focus on producing for you.” Here's what he recommends.

For months, kept under stealth mode was an emerging cell therapy company’s plans to spin out its development and manufacturing facility as a CDMO. No, not a stealth biotech. A stealth CDMO. Part 1 of an intriguing investigation.

Manufacturers must grapple with the environmental impact of oligonucleotide therapy production. Examine sustainable manufacturing processes that address environmental impact while maintaining scalability.

Due to its therapeutic impact on a wide range of diseases and disorders, AAV gene therapy is one of the most promising advances in modern medicine. Understand how AAV vectors and plasmids are produced.

There are a number of technology solutions that, when applied to a cell and gene therapy workflow, can streamline development and improve workflow integration.

Increased investment in allogeneic therapies and process-level advancements to achieve commercial scale are paving the way for streamlined, standardized cell therapy development and manufacturing.

Sponsors face pressure to balance speed, cost, and quality. Examine considerations to help you accelerate the delivery of transformative therapies while maintaining safety and upholding efficacy standards.

Learn how a recent expansion into Western Pennsylvania is aiming to enable more biopharma firms to translate cutting-edge science and research into practical applications.

Hear how the bioprocessing industry has evolved over the last few years and learn more about our investment in designing modular systems to help speed up the development of lifesaving therapies.

We set ambitious goals to provide competent capacity and capabilities, investing in, building, and ultimately deploying best-in-class viral vector manufacturing platforms that incorporate cutting-edge technologies.

Nanoplasmid’s small backbone and antibiotic-free selection system is designed for CGT applications. Its benefits include improved yields as compared to conventional plasmids and ITR stabilization.